Connect with us

Business

Markets End 4-Day Losing Streak, Sensex Closes At Points 85,265; Rupee Gains

Published

on

Markets End 4-Day Losing Streak, Sensex Closes At Points 85,265; Rupee Gains


Mumbai: Snapping a four-day losing streak, Indian stock markets ended higher on Thursday, helped by buying in IT shares as the rupee traded positive with gains against the US dollar.  

Gains, however, stayed modest as investors turned cautious ahead of the RBI Monetary Policy Committee’s decision scheduled for Friday.

The Sensex closed at 85,265.32, rising 158.5 points or 0.19 per cent. The Nifty also moved up, finishing at 26,033, higher by 47.75 points or 0.18 per cent.

Add Zee News as a Preferred Source


“The index mostly remained below the 21 EMA on the hourly chart, reflecting sustained selling pressure during the session,” analysts said.

“Technically, the 26,100–26,150 zone is expected to act as crucial resistance, while support is placed at 25,900–25,950,” they added.

“A fall below 26,000 may trigger a quick correction towards 25,950–25,900, as the chart setup appears weak on the hourly timeframe,” market watchers stated.

Broader market performance remained weak. The Nifty MidCap 100 index ended almost flat with a slight negative bias, while the Nifty SmallCap 100 slipped 0.24 per cent.

Among sectoral indices, Nifty IT was the biggest mover, jumping 1.4 per cent. Realty, FMCG, Auto, Pharma, Metal, and Chemical indices also saw buying interest.

On the other hand, Nifty Media dropped 1.45 per cent, and Bank, Financial Services, Consumer Durables, and Oil & Gas sectors also declined.

On the Sensex, the top gainers included TCS, Bharat Electronics, Tech Mahindra, Infosys, and HCL Tech.

Major laggards were Reliance Industries, Maruti Suzuki, Kotak Mahindra Bank, Titan, and Eternal.

Analysts said that the market managed a positive finish but stayed cautious as investors awaited key policy cues from the RBI.

“IT stocks outperformed, buoyed by renewed optimism around potential Fed rate cuts and favourable currency tailwinds, which strengthened investor appetite for the sector,” experts added.

Rupee traded positive with gains of 0.28 paise at 89.91 as markets await the RBI policy on Friday, especially after the currency hit all-time lows this week.

“Rupee range is seen between 89.80–90.25, with a breakout potentially taking it toward 89.25 on the upside or 90.75 on further weakness,” analysts said.



Source link

Business

FDA vaccine head will step down in April after string of controversial decisions

Published

on

FDA vaccine head will step down in April after string of controversial decisions


The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, April 22, 2025.

Nathan Posner | Anadolu | Getty Images

A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the agency following multiple decisions that raised concerns within the industry.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesperson confirmed on Friday. It is his second departure from the position: He briefly left the post in July following backlash over his regulatory decisions, and returned only two weeks later in August.

In a post on X, FDA Commissioner Marty Makary said the FDA will appoint a successor before Prasad returns next month to the University of California San Francisco, where he taught before taking the FDA position last year. Makary said Prasad “got a tremendous amount accomplished” during his tenure at the agency.

Prasad’s decision to step down comes after criticism of the FDA mounted within the biotech and pharmaceutical industry and among former health officials. In the past year, the agency has denied or discouraged the approval applications of at least eight drugs, according to RTW Investments, after taking issue with data the companies used to support their applications. The FDA also initially refused to review Moderna’s flu shot before it later reversed course.

All of those companies accused the FDA of reversing previous guidance about the evidence they could use to back their applications, sparking criticism within the industry that an unreliable regulatory process could stifle development of drugs for hard-to-treat diseases.

A former FDA official who spoke to CNBC on the condition of anonymity to speak freely on the issue called the reversals the worst kind of regulatory uncertainty because companies say they are being told one thing and then experience another.

In a statement earlier Friday, an FDA spokesperson said there was “no regulatory uncertainty,” adding the agency “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson said the FDA is “conducting rigorous, independent reviews and not rubber-stamping approvals.”

The most recent controversy came after the FDA discouraged UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease.

The agency, which underwent staff cuts and an overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., has faced broader backlash for its drug and vaccine approvals process. Critics have worried the agency could stifle the development of new treatments and risk the safety of patients.

The Wall Street Journal earlier reported Prasad’s departure.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Business

Oil price at two-year high after Qatar minister warns all Gulf production could stop

Published

on

Oil price at two-year high after Qatar minister warns all Gulf production could stop



Energy Minister Saad al-Kaabi says oil could hit $150 a barrel if the Iran conflict continues over the coming weeks.



Source link

Continue Reading

Business

Us India Oil Waiver: ‘Releases the pressure on other refineries’: US says India’s Russian oil waiver is a short-term step to stabilise global prices – The Times of India

Published

on

Us India Oil Waiver: ‘Releases the pressure on other refineries’: US says India’s Russian oil waiver is a short-term step to stabilise global prices – The Times of India


The United States has said its decision to grant India a temporary waiver to purchase certain Russian oil supplies is a short-term move aimed at stabilising global crude prices amid supply disruptions linked to tensions in the Middle East.US energy secretary Chris Wright said the measure is intended to quickly bring oil stored in floating reserves into the global market and ease immediate supply constraints.

US Allows India To Buy Russian Oil As Allies Offer Gas Supplies Amid Iran War And Hormuz Tensions

Speaking to ABC News Live, Wright said large volumes of Russian crude are currently stored in tankers around southern Asia and that Washington had encouraged India to buy these cargoes.“We need to get oil on the market in the short term. In the long term, supplies are abundant. There’s no worry there,” Wright said, adding that the temporary step was necessary as oil prices were rising due to constraints in shipments passing through the Strait of Hormuz.“As oil gets bid up a little bit because of those constraints coming out of the Straits of Hormuz, we’re taking a short-term action to say all this floating Russian oil storage that’s around southern Asia,” he said.Wright said the US had asked India to absorb those cargoes. “We’ve reached out to our friends in India and said, ‘Buy that oil. Bring it into your refineries.’ That pulls stored oil immediately into Indian refineries and releases the pressure on other refineries around the world,” he added.He stressed that the waiver does not represent a shift in Washington’s stance toward Moscow. “This is no change in policy towards Russia. This is a very brief change in policy just to keep oil prices down a little bit better than we could otherwise,” Wright said.Earlier in the day, US treasury secretary Scott Bessent announced a 30-day waiver allowing Indian refiners to purchase Russian oil cargoes stranded at sea.“To enable oil to keep flowing into the global market, the treasury department is issuing a temporary 30-day waiver to allow Indian refiners to purchase Russian oil,” Bessent said in a post on X.

Indian refiners step up purchases

Following the waiver, Indian refiners have begun purchasing large volumes of Russian oil floating in Asian waters, reported news agency PTI, citing sources.The companies have snapped up around 20 million barrels of crude, mostly from non-sanctioned entities, though they are seeking legal clarity on whether the exemption also allows purchases from sanctioned firms.The US Treasury’s Office of Foreign Assets Control has issued a licence permitting the delivery and offloading of Russian crude loaded on vessels before March 5, 2026, with transactions allowed until April 4, 2026.The move comes as the widening West Asia conflict disrupts energy shipments through the Strait of Hormuz, through which nearly 40–50 per cent of India’s crude imports typically pass.India, which holds reserves covering roughly 25 days of crude demand, has turned to Russian cargoes at sea to ensure domestic fuel supplies remain stable. Indian refiners had already been importing about one million barrels of Russian oil per day in recent months.Industry estimates cited by PTI suggest around 15 million barrels of Russian crude are currently floating in the Arabian Sea and the Bay of Bengal, while additional cargoes are waiting near Singapore and other routes that could reach Indian ports within weeks.Analysts say the waiver provides short-term relief for India’s energy security, though competition from other buyers, particularly China, may limit the volume of additional Russian oil available.



Source link

Continue Reading

Trending